Nicole Lambert
Vermögen: 1 Mio $ am 31.05.2026
Vermögen: 1 Mio $ am 31.05.2026
Ms. Nicole Lambert is an Independent Director at Arcus Biosciences, Inc. and a President at Myriad Genetic Laboratories, Inc. She is on the Board of Directors at Arcus Biosciences, Inc. Ms. Lambert was previously employed as a Chief Operating Officer by Myriad Genetics, Inc. She received her undergraduate degree from Boston College and a graduate degree from Icahn School of Medicine at Mount Sinai.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ARCUS BIOSCIENCES, INC. 0,03 % | 11.06.2026 | 43 000 ( 0,03 % ) | 1 Mio $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| ARCUS BIOSCIENCES, INC. | Direktor/Vorstandsmitglied | 03.08.2021 |
Myriad Genetic Laboratories, Inc.
Myriad Genetic Laboratories, Inc. Miscellaneous Commercial ServicesCommercial Services Provides cancer predisposition testing services | Präsident | - |
| Unternehmen | Position | Ende |
|---|---|---|
| MYRIAD GENETICS, INC. | Geschäftsführer | 31.10.2023 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 5 |
|---|---|
Myriad Genetics, Inc.
Myriad Genetics, Inc. Medical SpecialtiesHealth Technology Develops therapeutic and predictive medicine products | Health Technology |
Boston College
Boston College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Icahn School of Medicine at Mount Sinai
Icahn School of Medicine at Mount Sinai Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Myriad Genetic Laboratories, Inc.
Myriad Genetic Laboratories, Inc. Miscellaneous Commercial ServicesCommercial Services Provides cancer predisposition testing services | Commercial Services |
Arcus Biosciences, Inc.
Arcus Biosciences, Inc. BiotechnologyHealth Technology Develops and commercializes novel therapies for the treatment of lung & gastrointestinal cancers | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen